Private equity’s growing presence in American healthcare has long walked a tightrope between efficiency and intrusion. What once made the sector an appealing target – stable revenue streams, fragmented markets, and regulatory nuance – is now drawing increasing scrutiny.
But while federal policymakers once led the charge, today’s spotlight has shifted.